GPR

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S2637 Fasiglifam (TAK-875) <1 mg/mL 100 mg/mL <1 mg/mL
S2149 GSK1292263 <1 mg/mL 34 mg/mL <1 mg/mL
S8014 GW9508 <1 mg/mL 69 mg/mL 69 mg/mL
S7263 AZD1981 <1 mg/mL 11 mg/mL <1 mg/mL
S2822 OC000459 <1 mg/mL 4 mg/mL <1 mg/mL
Catalog No. Information Product Use Citations Product Validations
S2637

Fasiglifam (TAK-875)

Fasiglifam (TAK-875) is a selective GPR40 agonist with EC50 of 14 nM in human GPR40 expressing CHO cell line, 400-fold more potent than oleic acid.

S2149

GSK1292263

GSK1292263 is a novel GPR119 agonist, showing potential for the treatment of type 2 diabetes. Phase 2.

S8014

GW9508

GW9508 is a potent and selective agonist for FFA1 (GPR40) with pEC50 of 7.32, 100-fold selective against GPR120, stimulates insulin secretion in a glucose-sensitive manner.

S7263

AZD1981

AZD1981 is a potent, selective CRTh2 (DP2) receptor antagonist with IC50 of 4 nM, showing >1000-fold selectivity over more than 340 other enzymes and receptors, including DP1. Phase 2.

S2822

OC000459

OC000459 is a potent and selective D prostanoid receptor 2 (DP2) antagonist with IC50 of 13 nM. Phase 2.

S4709

Latanoprost

Latanoprost is a prostaglandin F2alpha analogue and a prostanoid selective FP receptor agonist with an ocular hypertensive effect. Latanoprost increases uveoscleral outflow and thereby reduces intraocular pressure.